a once-daily dry powder inhaler for treatment of COPD in routine clinical practice in a new-user, 1:1 propensity score-matched cohort study. The study included 20,388 propensity score-matched ...

UK pharma major AstraZeneca’s Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window There was a ...

As the doctors told Annette Stalley she might need to be put on a ventilator, she realised it was a situation of her own ...

Dr. Andy Whittamore, a GP and clinical lead at Asthma and Lung UK, shed light on four chronic lung conditions that tend to deteriorate in winter. From asthma to more uncommon ailments like ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Study AER-01-002 is using a novel and precision imaging strategy to enroll 100 mucus plug-high chronic obstructive pulmonary disease (COPD) patients AER-01-002 is well powered to determine if 28-days ...

a once daily dry powder inhaler, in patients with chronic obstructive pulmonary disease (COPD) treated in routine clinical practice. Design New user cohort study. Setting Longitudinal commercial US ...

After waking up from the procedure, he told me he could take full breaths for the first time in years,” Dr. Mark Sigler said ...

USA 2 Division of Pulmonary and Critical Care Medicine, Department of Medicine, Brigham and Women’s Hospital, Boston, MA, USA Objective To compare the effectiveness and safety of ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...